Drugs / G03-52-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04171115 | Jun 2020 → Aug 2022 | — | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05348993 | Jun 2022 → Feb 2025 | salivary substance, Clostridium botulinum type | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G03-52-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04171115 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT04171115 ↗ |